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SUPPLEMENTARY INFORMATION 
 
Supplement Appendix 1. Sponsor and Author Responsibilities, Exclusion 
Criteria, Description of Blinding Methods, Additional Statistical Methods, 
EDN Assay, and Steroid Conversion Table. 
 
Statement of Responsibilities  
The study was jointly designed by members of an expert HES investigator 
advisory board (composed of the authors and other experts) and the sponsor, 
with scientific guidance regarding study design received from the FDA in the US 
and CPMP in Europe. The primary author participated in the initial presentation 
of the study to the FDA. The sponsor had responsibility for data collection and 
quality control, and all authors were involved in data analysis and interpretation. 
The data was made available to authors via hard copies and a web-based portal 
access system. Per the protocol, a sponsor committee consisting of a physician 
and statistician, who were not directly involved with the study, conducted an 
Interim Review of Safety Data at two time points during the conduct of the study. 
The findings from this review committee were transmitted to Investigators and 
IRB/ethics committees. The authors decided to publish the paper, all contributed 
to the writing of the manuscript via a series of email exchanges and 
teleconferences, and approval from all authors was required. The EDN analysis 
was performed by Dr Gerald Gleich’s laboratory. Editorial assistance was 
provided by two professional medical writers who are listed in the 
acknowledgments. 
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Exclusion criteria 
Exclusion criteria were life-threatening HES or other serious illness; eosinophilia 
owing to drug eruption or parasitic infection in the previous year, graft-versus-
host disease, bullous pemphigoid, cystic fibrosis, rheumatoid arthritis, or HIV 
infection; Churg-Strauss syndrome; Wegener's granulomatosis; malignancy; 
severely abnormal laboratory tests; severe cardiac dysfunction; or drug or 
alcohol abuse in the preceding 6 months. Known hypersensitivity to antibody 
therapy, prior anti-human IL-5 monoclonal antibody therapy, treatment with an 
investigational drug in the previous 30 days, and pregnancy were additional 
exclusion criteria. The Institutional Review Board or Independent Ethics 
Committee of each site approved the protocol, and all patients provided written 
informed consent. The study adhered to Good Clinical Practice and the principles 
of the Declaration of Helsinki. 
 
Methods for Randomization 
Study subjects were randomized centrally through an Interactive Voice Response 
System. A randomization schedule, within the two strata based upon subjects' 
entry prednisone (or equivalent) daily dose of ≤30mg or >30mg, was generated 
by GlaxoSmithKline Biomedical Data Sciences using randomly permuted blocks. 
Subjects in each stratum were randomized in a 1:1 ratio to receive either 750 mg 
mepolizumab intravenous (IV) infusion or saline (as placebo) IV infusion, every 4 
weeks beginning from Day 1 until the last infusion at Week 32. 
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Because mepolizumab for injection is provided as open-label vials to the study 
sites, third party blinding was employed to ensure the subjects, investigators, and 
all who were involved in the evaluation of the study subjects were blinded to a 
subject's treatment assignment until the closure of the database after study 
completion. 
 
Statistical Methods  
A sample size of 84 evaluable patients (42 per treatment group) was estimated to 
provide 90% power at a 5% two-sided significance level to detect a difference of 
33% between treatment groups in the primary end point (assuming the proportion 
achieving a prednisone dose of ≤10 mg per day for ≥8 weeks was 80% and 47% 
in the mepolizumab and placebo groups, respectively). Differences in response 
rates between mepolizumab and placebo in the primary end point were tested 
using a Cochran Mantel-Haenszel test, stratifying by baseline prednisone (or 
equivalent) dose level (≤30 mg or >30 mg), at a 5% two-sided significance level 
in the ITT population. Odds ratios (OR; primary pre-specified analysis), relative 
risks (not stratified by baseline prednisone dose level), and hazard ratios of the 
time-to-achieving the end point (stratified by baseline prednisone dose level) 
were also calculated. 
 
Adverse events were summarized. A log-rank test was used to compare the time 
taken to experience an adverse event between treatments, which takes into 
account patients who withdrew from the study. 
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Secondary end points were analyzed as follows: binary responder/nonresponder 
end points were analyzed in the same way as the primary end point, time-to-
treatment failure was analyzed using the stratified log-rank test (adjusted for 
baseline prednisone dose level) to test for differences between treatments, and 
the prednisone dose at Week 36 was analyzed using an analysis of covariance 
(adjusted for baseline prednisone dose level). The last available on-treatment 
prednisone dose was carried forward for patients missing Week 36 data. 
 
The differences in response rates between mepolizumab and placebo for the 
primary endpoint and the eosinophil secondary endpoint in each of the baseline 
prednisone dose subgroups (≤30 mg and >30 mg) were tested using a Chi-
squared test. 
 
An exploratory sensitivity analysis of the primary endpoint using logistic 
regression was pre-planned. The statistical model on which inference was based 
included terms for baseline prednisone (or equivalent) dose level category (≤30 
mg, >30 mg) and treatment group, regardless of their significance. Additionally, 
other terms were tested in a model-building approach and included if statistically 
significant (P<0.05). The model building utilized a forward selection method, i.e. 
each term was added in turn and the term that gave the greatest significant 
reduction in deviance was included in the model. This continued until all terms 
giving a significant reduction in deviance were in the model. No interaction terms 
were included in this model.  
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Measurement of Eosinophil-derived Neurotoxin (EDN) 
Sera were collected from study patients at four different time points, baseline, 12 
weeks, 24 weeks and 36 weeks, respectively.  EDN was assayed using 
chemiluminescence immunoassay technology and two monoclonal antibodies.  
Briefly, sera were incubated in plates coated with J167-6C5 capture antibody, 
washed and incubated with acridinium labeled J167-2G4 anti-EDN detection 
antibody.  After a final wash, EDN was measured using a LMAX II384 
luminometer (Molecular Devices) and the SOFTmax® PRO (ver.4.6) Software 
(Molecular Devices, Sunnyvale, CA). The authors are grateful to Ann Georgelas 
and Saritha Tunuguntla  (University of Utah) for expeditious completion of the 
EDN assays. The differences in the EDN data between mepolizumab and 
placebo were tested using the Kruskal Wallis test. 
 
Steroid Conversion Table: 
Alternate Corticosteroid Equivalent Dose to Prednisone 1 mg 
(Multiplier) 
 Methylprednisolone 0.8 mg (1.25) 
 Prednisolone 1 mg (1) 
 Triamcinolone 0.8 mg (1.25) 
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Supplement Appendix 2. Serious Adverse Events From the Mepolizumab in 
HES Trial (Study MHE100185). 
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Listing of Serious Adverse Events 
Pt Patient age, y & 
gender (M/F) 
Study drug Serious adverse 
event 
Intensity Day of 
onset* 
Outcome Duration Relationship 
to study drug† 
Action 
taken 
A 36 (F) Placebo  HES relapse Severe 59 Recovered/resolved 17 days Unrelated No action 
B 43 (F) Placebo Pneumonia Moderate 30 Recovered/resolved 9 days Unrelated No action 
C 62 (F) Placebo Dysaesthesia Mild 9 Recovering/resolving Ongoing Unrelated No action 
   Eosinophilia Moderate 163 Recovered/resolved 14 days Unrelated Study drug withdrawn 
   Polyneuropathy Moderate 163 Recovered/resolved 14 days Unrelated Study drug withdrawn 
D 46 (M) Mepolizumab 750 mg Hepatitis Severe 94 Recovered/resolved 7 days Unrelated No action 
   Rhinitis Mild 258 Recovered/resolved 12 days Unrelated No action 
E 52 (F) Mepolizumab 750 mg Asthma exacerbation Moderate 135 Recovered/resolved 45 days Unrelated No action 
   Bronchitis Moderate 135 Recovered/resolved 45 days Unrelated No action 
   Dehydration Moderate 144 Recovered/resolved 4 days Unrelated No action 
F 18 (M) Mepolizumab 750 mg Asthma exacerbation Moderate 107 Recovered/resolved 28 days Unrelated No action 
   HES relapse (GI) Severe 111 Recovered/resolved 24 days Unrelated No action 
G 19 (M) Mepolizumab 750 mg Renal failure Severe 1 Recovered/resolved 4 days Unrelated No action 
H 18 (M) Mepolizumab 750 mg Pyrexia Mild 76 Recovered/resolved 5 days Unrelated No action 
   Renal failure Severe 98 Ongoing until death‡ — Unrelated No action 
   Cardiac arrest Severe 109 Fatal 2 days Unrelated Study drug withdrawn 
I 50 (M) Placebo Osteonecrosis (hip) Severe 98 Not recovered/not resolved Ongoing Unrelated No action 
J 44 (M) Mepolizumab 750 mg Pancreatitis Severe 74 Recovered/resolved 42 days Unrelated No action 
   Pancreatitis Severe 237 Recovered/resolved 93 days Unrelated No action 
K 72 (F) Mepolizumab 750 mg Pneumonia Moderate 161 Recovered/resolved 35 days Unrelated No action 
   Spinal compression fracture (T12) Severe 202 Recovering/resolving Ongoing Unrelated No action 
L 33 (M) Placebo  Nephrotic syndrome Moderate 129 Recovering/resolving Ongoing Unrelated Study drug withdrawn 
*Days since first infusion of investigational product; †Relationship to study drug was assessed by the investigator; ‡Subject died due to a cardiac arrest on Day 111 
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Safety Narratives for All Serious Adverse Events Reported During Study 
MHE100185 
 
Patient A 
Suspect Drugs: Placebo 
Serious Events: Hypereosinophilic syndrome 
This 36-year-old female subject was enrolled in a blinded study for the treatment 
of hypereosinophilic syndrome, receiving intravenous investigational product 
every 4 weeks. 
The subject developed abdominal pain with symptoms of itching, urticaria, 
and vomiting 59 days after the start of investigational product, and developed 
asthma 2 weeks later. The subject was hospitalized and diagnosed with severe 
relapse of hypereosinophilic syndrome. Relevant test results included an 
elevated eosinophil count of 1000/mm3 (normal <500/mm3) and an elevated C-
reactive protein level of 24.2 mg/L (normal <6 mg/L). The subject was treated 
with prednisone, oxygen therapy, amoxicillin trihydrate, and salbutamol sulphate. 
Concomitant medications included levocetirizine hydrochloride (Xyzal).  
Treatment with investigational product was not stopped because of these 
events. The relapse of hypereosinophilic syndrome resolved after 17 days, and 
the subject was discharged the following day. The investigator considered there 
was no reasonable possibility that the relapse of hypereosinophilic syndrome 
may have been caused by the investigational product. The investigator also 
considered the relapse of hypereosinophilic syndrome to be possibly associated 
with the disease under study. 
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Patient B 
Suspect Drugs: Placebo 
Serious Events: Pneumonia 
This 43-year-old female subject was enrolled in a blinded study for the treatment 
of hypereosinophilic syndrome. The subject received intravenous investigational 
product for 1 month. 
Thirty days after the start of investigational product and 2 days after the 
most recent dose, the subject developed confusion, loss of bladder control, and 
diarrhea. A chest x-ray showed dense infiltrates in the right lung and laboratory 
results showed a high white blood cell count and hypoxia. A neurologic exam 
showed that the subject was disoriented to time and had decreased word-finding 
ability. She was hospitalized and diagnosed with pneumonia. The subject began 
treatment with levofloxacin. Concomitant medications included amitriptyline, 
prednisone, temazepam, and cyclobenzaprine. The event resolved after 9 days, 
and the subject was discharged. The investigator considered there was no 
reasonable possibility that the pneumonia may have been caused by the 
investigational product. The disease under study and the subject's concurrent 
medical conditions of asthma and shortness of breath were cited as possible 
causes. 
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Patient C 
Suspect Drugs: Placebo 
Serious Events: Dysaesthesia, Eosinophilia, Polyneuropathy 
This 62-year-old female subject was enrolled in a blinded study for the treatment 
of hypereosinophilic syndrome, and received blinded investigational product. 
Nine days after the start of investigational product, the subject developed 
increased dysaesthesia and hypoesthesia in both feet, and was hospitalized as a 
result of the dysaesthesia. The subject had a slight increase in dyspnea and 
cough. Treatment with investigational product was continued. A neurologic 
examination (electroneurography and myography) 5 days later showed no signs 
of increased disease activity, and the dysaesthesia was unresolved at this time. 
Concomitant medications included prednisone (Prednison), alendronate sodium 
(Fosamax), and ossofortin forte. The investigator considered there was no 
reasonable possibility that the dysaesthesia may have been caused by 
investigational product. The investigator also considered the event to be possibly 
associated with the disease under study. 
Approximately 5 months (163 days) after the start of investigational 
product, the subject developed grade 2 (or moderate) dysaesthesia in both legs 
with an increase of inflammation markers and eosinophils. The subject was 
hospitalized. Relevant test results included eosinophils 1185 cells/µL and C-
reactive protein 11.0 mg/L (normal ranges not provided). The subject recovered 
14 days after event onset. The investigator considered that there was no 
reasonable possibility that the events may have been caused by investigational 
product and that the events were possibly due to lack of efficacy and disease 
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under study. Treatment with investigational product was discontinued after the 
sixth infusion, the subject was withdrawn from the study, and was enrolled into 
the open-label study.  
The final diagnosis was considered to be polyneuropathy and eosinophilia. 
The events were considered unrelated to investigational product. 
 - 12 - 
 
 
Patient D 
Suspect Drugs: Mepolizumab 
Serious Events: Hepatitis, Rhinitis 
This 46-year-old male subject was enrolled in a blinded study for the treatment of 
hypereosinophilic syndrome. The subject received intravenous investigational 
product every 4 weeks. 
Ninety-four days after the start of investigational product, and 9 days after 
the most recent dose, the subject developed fever with a body temperature of 
39°C. The subject was hospitalized 4 days later. Blood cultures were negative. 
Liver function tests showed that aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels were elevated. Results for AST were 81 U/L at 
admission, 150 U/L and 205 U/L at 1 day post-admission, 139 U/L at 2 days 
post-admission, and 46 U/L at 3 days post-admission (normal range 17–59 U/L). 
Results for ALT were 107 U/L at admission, 180 U/L and 249 U/L at 1 day post-
admission, 273 U/L at 2 days post-admission, and 165 U/L at 3 days post-
admission (normal range 21–72 U/L). The subject was diagnosed with hepatitis. 
Results of bone marrow analysis were normal. Tests for Hepatitis A, B, and C, 
CMV, and EBV were all negative. The subject was treated with corticosteroids 
(Medrol), cefepime (Maxipime), paracetamol (Perfusalgan), and amoxicillin 
trihydrate plus potassium clavulanate (Augmentin). 
Treatment with investigational product was not stopped because of this 
event. The event resolved after 7 days. The investigator considered there was no 
reasonable possibility that the hepatitis may have been caused by the 
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investigational product. The investigator also considered the hepatitis to be 
possibly associated with the disease under study. 
Approximately 8 months after the start of investigational product, the 
subject developed mild rhinitis and a fever. He was hospitalized and was treated 
with amoxicillin trihydrate + potassium clavulanate (Augmentin) and amoxicillin 
trihydrate + potassium clavulanate (Amoxiclav).  
Treatment with investigational product was not stopped because of this 
event. The subject was discharged and the event resolved after 12 days’ 
duration. The investigator considered there was no reasonable possibility that the 
rhinitis may have been caused by the investigational product. The cause of the 
rhinitis was cited as unknown. 
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Patient E 
Suspect Drugs: Mepolizumab 
Serious Events: Asthma, Bronchitis, Dehydration 
This 52-year-old female subject was enrolled in a blinded study for the treatment 
of hypereosinophilic syndrome. The subject began to experience flu-like 
symptoms 135 days after the start of treatment with intravenous investigational 
product and 23 days after receiving her last dose. She was hospitalized with an 
exacerbation of asthma and bronchitis. The subject was treated with levofloxacin 
(Levaquin), Combivent, and prednisone and the events improved. The symptoms 
resolved after 45 days.  
Nine days later, the subject experienced dehydration. A chest x-ray was 
normal but her white blood cell count and neutrophil count were both elevated. 
She was treated with intravenous fluids and the dehydration resolved after 4 
days. 
The investigator considered there was no reasonable possibility that the 
asthma exacerbation, bronchitis, and dehydration may have been caused by 
investigational product. Medical conditions at the time of the event included 
asthma, fibromyalgia, and smoking. Concurrently, she received fluticasone. 
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Patient F 
Suspect Drugs: Mepolizumab 
Serious Events: Asthma, Hypereosinophilic syndrome 
This 18-year-old male subject was enrolled in a blinded study for the treatment of 
hypereosinophilic syndrome. Medical conditions included asthma and acne. 
Concomitant medications included erythromycin (Eryfluid), fluticasone propionate 
+ salmeterol xinafoate (Seretide), and montelukast sodium (Singulair). Treatment 
with concurrent montelukast sodium was stopped 4 months after study entry. 
During the run-in period, the subject received treatment with prednisolone, 
which was tapered from 50 mg/day to 2.5 mg/day over 13 weeks. The subject 
received intravenous investigational product every 4 weeks. The subject 
experienced non-serious abdominal pain and vomiting 107 days after the start of 
treatment with investigational product, and 26 days after administration of the 
previous (fourth) dose. Additionally, the subject developed a moderately severe 
exacerbation of asthma. Four days later, the subject developed a severe 
gastrointestinal relapse of underlying hypereosinophilic syndrome.  
On the day of the fifth infusion of the investigational product, the subject 
had an eosinophil count of 0.2×109/L (normal range: 0–0.8×109/L), monocyte 
count of 1.0×109/L (normal range: 0.2–1.0×109/L), platelet count of 322×109/L 
(normal range: 150–400×109/L), and white blood cell count of 9.53×109/L (normal 
range: 4–10×109/L). Three days later, the subject was hospitalized due to eating 
difficulties with vomiting and abdominal pain with complete food intolerance. At 
this time, the subject's eosinophil count was 0.2×109/L. Other laboratory results 
showed a platelet count of 318×109/L, elevated monocyte count of 1.4×109/L, 
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and white blood cell count of 8.22×109/L. The subject received treatment with 
methylprednisolone 250 mg/day and the symptoms disappeared; the subject 
then started treatment with prednisolone 10 mg/day. An abdominal plain x-ray 
showed few median air-fluid levels and no pneumoperitoneum. 
One week after hospitalization, the eosinophil count had increased to 
0.63×109/L, monocyte count and white blood cell count were elevated at 
1.4×109/L and 13.2×109/L, respectively, and platelet count was normal at 
368×109/L. The subject relapsed the next day and, 3 days later, received an 
increased dose of background prednisone up to 20 mg/day. The gastrointestinal 
symptoms resolved after 24 days, when the eosinophil count was 0.6×109/L; the 
subject also had an elevated white blood cell count of 13.3×109/L and a platelet 
count of 314×109/L. The subject was treated with fluticasone propionate, 
salmeterol and montelukast sodium, which was later stopped. The exacerbation 
of asthma was also considered resolved after 28 days. Treatment with the 
investigational product was continued. 
The investigator considered that there was not a reasonable possibility the 
asthma exacerbation and digestive relapse of hypereosinophilic syndrome were 
related to treatment with the investigational product. The investigator reported 
that the relapse of hypereosinophilic syndrome was related to the subject's 
participation in the study, since it did not allow him to maintain background 
corticosteroid therapy. The disease under study and its treatment failure were 
cited as possible causes of the event. 
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Patient G 
Suspect Drugs: Mepolizumab 
Serious Events: Renal failure 
This 19-year-old male subject was enrolled in a blinded study for the treatment of 
hypereosinophilic syndrome. The subject was known to have eosinophilic renal 
infiltration and episodes of acute renal failure.  
On the day of commencing the investigational product, the subject was 
hospitalized with a diagnosis of severe renal failure. The subject was treated with 
intravenous and oral prednisolone. Treatment with investigational product was 
continued. The renal failure resolved after 4 days, and the subject was 
discharged from hospital. The investigator considered there was no reasonable 
possibility that the renal failure may have been caused by investigational product. 
The investigator also considered the event to be possibly associated with the 
disease under study. The renal failure was considered to be related to the 
subject’s history of renal failure. 
Follow up information revealed that the subject experienced hematuria 
without pain. The subject underwent an examination, which consisted of a 
cytoscopy and an intravenous urography. 
Follow-up laboratory information also revealed that the subject had a low 
creatinine level 1 week prior to administration of the first dose of investigational 
drug at 58 μmol/L and creatinine clearance of 2.75 mL/sec. Furthermore, 
laboratory studies obtained on the day of the first infusion included total protein of 
37 g/L (normal range 60–83 g/dL), albumin 12 g/L (35–48 g/L), urea 14.8 mmol/L 
(1.8–6.4 mmol/L), sodium 133 mmol/L (136–146 mmol/L), and C-reactive protein 
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9.1 mg/L (normal range not provided). Additionally, the subject had a history of 
renal failure for 2–5 years, which usually correlated with rise in eosinophil count 
and reduction in prednisolone. 
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Patient H 
Suspect Drugs: Mepolizumab, Mepolizumab, Warfarin sodium 
Serious Events: Fatal cardiac arrest, Pyrexia, Renal failure 
This 18-year-old male subject was enrolled in an open-label study for the 
treatment of hypereosinophilic syndrome. The subject's past medical history 
included amputation of digits of hands (due to vasculitis) and of left foot, asthma, 
atrioventricular block, deep vein thrombosis, defibrillator insertion, 
gastrointestinal infection, myocarditis, pulmonary embolism, renal calculus, 
retroperitoneal hemorrhage, seizures, and vena cava filter insertion. The subject 
received four doses of intravenous mepolizumab. 
The subject developed bloody stools 76 days after the start of 
investigational product and 20 days after the most recent dose. He also 
presented with shortness of breath, fever, wheezing, anemia, renal insufficiency, 
and hyperuricemia. The subject was hospitalized at that time, because of a fever 
of 101.7°F, which was considered severe. Fever was treated with intravenous 
vancomycin and imipenem/cilastatin (Primaxin). The subject remained afebrile 
during the remainder of hospitalization. Both the bloody stools and fever resolved 
after a total duration of 5 days. Chest x-ray on admission showed pleural 
effusion. The subject’s creatinine on admission was 2 mg/dL and the subject was 
treated with intravenous fluids. Creatinine on discharge was 1.5 mg/dL. While 
hospitalized, his hematocrit dropped from 35.7% to 31.8% and remained stable 
with a discharge value of 31.2%. Treatment with investigational product was 
continued. The investigator considered there was no reasonable possibility that 
the fever may have been caused by investigational product. The investigator also 
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considered the bloody stools, shortness of breath, and fever to be possibly 
associated with medical conditions of fluid overload and coagulopathy and 
concomitant medication, coumadin.  
On follow-up, the investigator reported that a discharge note indicated the 
subject had a proctoscopy, which revealed external and internal hemorrhoids. 
The subject was treated with hemorrhoidal cream. 
Subsequently, 98 days after the start of investigational product, the 
subject developed renal failure, was hospitalized, and treated with fluids. At time 
of reporting, the subject was improving. In the investigator's opinion, the renal 
failure was unrelated to treatment with investigational product. Upon follow-up, 
the investigator reported the subject's fractional extraction of sodium was less 
than 1%. A renal sonogram was performed to rule out obstructive causes of renal 
failure. The subject was initially treated with intravenous normal saline and the 
acute renal failure progressively improved during the hospital stay. The subject's 
creatinine value at discharge was 1.3 mg/dL.  
Medical conditions at the time of the event included allergy to angiotensin-
converting enzyme (ACE) inhibitors, allergy to heparin and penicillin, colitis, 
dilated cardiomyopathy, gangrene of toe, hypereosinophilic syndrome, Loeffler's 
endocarditis, three myocardial infarctions, Raynaud’s phenomenon, renal 
insufficiency, and systemic hypertension. Concomitant medications included 
prednisone, Lexapro, warfarin sodium, losartan, allopurinol, pantoprazole, 
furosemide, and carvedilol. 
The subject experienced cardiac arrest 109 days after the start of 
mepolizumab treatment. He had passed out at home and his body felt cold. No 
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immediate cardiopulmonary resuscitation (CPR) was performed and an 
ambulance was requested. Paramedics performed CPR, intubated, and 
transported him to the emergency department where he received CPR, 
defibrillations, and amiodarone, and was then stabilized. Troponin level in 
emergency department was 7.07 ng/mL (normal: <0.10). The subject was also 
treated with atropine. The emergency department was unable to review systems 
owing to the critical nature of the subject's condition. The subject was placed on 
dopamine HCL and transferred to intensive care. Vital signs showed temperature 
of 92°F and pulse 94. The maximum dose of dopamine was administered and 
the subject was treated with Levophed. The subject became unresponsive with 
dilated and fixed pupils. The subject was also in acute respiratory failure. 
Advanced cardiac life support followed—CPR was performed for 30 minutes, but 
the subject died of cardiac arrest the following day. The investigator considered 
that there was no reasonable possibility that the cardiac arrest may have been 
caused by mepolizumab and that the events were possibly due to acute 
respiratory failure, gangrene, acute and chronic renal insufficiency, and 
hypereosinophilic syndrome with end-stage multiorgan involvement. 
Follow-up received from medical records included the following: 
prednisone was tapered from 50 mg/day at baseline to a dose of 2.5 mg/day 
after 11 weeks. The total dose was subsequently increased to 15 mg/day, which 
was continued until the subject's death. Eosinophil counts were controlled from 
baseline for approximately 3 months, when the final dose of investigational 
product was administered. However, 3 days prior to the cardiac arrest, eosinophil 
counts increased above the pre-dose levels to 2840 cells/µL. Two 
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echocardiograms were reported pretreatment. Approximately 5 weeks prior to 
administration of the first dose of mepolizumab, left ventricular ejection fraction 
was estimated at 35–40%. Repeat echocardiogram on the day the first 
mepolizumab dose was administered showed that left ventricular function had 
deteriorated substantially, and the left ventricular ejection fraction was estimated 
at 25–30%. 
Pre-dose electrocardiogram (ECG) results on the day of the first dose of 
mepolizumab showed a normal PR interval, normal sinus rhythm, rate 70 bpm, 
QRSD bifascicular block, right bundle branch block, and left posterior fascicular 
block, QT consider left atrial enlargement, QTc consider left ventricular 
hypertrophy with ST-T abnormalities, and late T wave abnormalities. ECG results 
remained unchanged through to the day of the last mepolizumab infusion. 
Two months after the patient’s death, a meeting was held between the 
investigator and GlaxoSmithKline, which provided additional information. A 
postmortem was not performed. The cause of death on the discharge summary 
was cardiac arrest. It was concluded that this was due to dysrhythmia which was 
similar to previous episodes and attributed to the failure of the internal 
pacemaker/defibrillator. It was confirmed that the echocardiograms on trial drug 
did not show evidence of deterioration, but there was deterioration between the 
screening and baseline echocardiograms. There was no clinical evidence of 
failure to control the hypereosinophilic syndrome during the first 3 months of the 
trial. Up to this time, the patient had been clinically stable with no clinical 
evidence of worsening cardiac disease. The hypereosinophilic syndrome was 
very severe, having only been present for slightly more than a year, but being 
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associated with finger amputations due to vasculitis, lung, gut, and cardiac organ 
damage. 
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Patient I 
Suspect Drugs: Placebo 
Serious Events: Osteonecrosis 
This 50-year-old male subject was enrolled in a blinded study for the treatment of 
hypereosinophilic syndrome. The subject received intravenous investigational 
product for 85 days before being withdrawn and enrolled in the open label 
extension study. Ninety-eight days after the start of investigational product and 
17 days after receiving the fourth dose of investigational product, the subject 
complained of left hip pain that necessitated the use of a cane. He underwent 
magnetic resonance imaging, which revealed bilateral avascular necrosis of the 
hip. The event was considered disabling and he was referred to an orthopedic 
surgeon for treatment. His pain was being controlled by ibuprofen (Motrin) and 
Tylenol #3. The subject underwent bilateral hip replacement and is doing well. 
Medical conditions at the time of the event included persistent eosinophilia. 
Concomitant medications included high-dose prednisone (>20 mg/day). The 
investigator considered there was no reasonable possibility that the avascular 
necrosis may have been caused by investigational product, but that it may 
possibly have been associated with prednisone therapy. 
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Patient J 
Suspect Drugs: Mepolizumab 
Serious Events: Pancreatitis  
This 44-year-old male subject was enrolled in a blinded study for the treatment of 
hypereosinophilic syndrome. The subject's past medical history included kidney 
stone and pancreatitis possibly related to microlithiasis. 
The subject developed severe left lower abdominal pain, flushing, 
sweating, nausea, and fever 74 days after the start of investigational product. 
The subject was hospitalized for further work-up and evaluation. Kidney stones 
were ruled out via computed tomography and the subject was diagnosed with 
pancreatitis. An abdominal ultrasound showed no evidence of gallbladder stones 
or signs of gall bladder wall thickening. Relevant laboratory tests showed an 
elevated lipase level of 1264 IU/L. The subject was treated with normal saline, 
potassium, hydromorphone (Dilaudid), morphine, and antibiotics (unspecified). 
Treatment with investigational product was continued. The subject's condition 
significantly improved and he was discharged home after a week. The 
pancreatitis subsequently resolved 42 days after initial onset. Medical conditions 
at the time of the event included gastroesophageal reflux disease and 
hypertension. Concomitant medications included cetirizine hydrochloride 
(Zyrtec), lisinopril (Zestril), omeprazole (Prilosec), atorvastatin calcium (Lipitor), 
methylphenidate hydrochloride (Concerta), and fluticasone propionate (Flovent). 
The investigator considered there was no reasonable possibility that the 
pancreatitis may have been caused by investigational product. The investigator 
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also considered the pancreatitis to be possibly associated with an infection or an 
unknown cause. 
Subsequently, 237 days after the start of investigational product, the 
subject developed acute abdominal pain and fever. The subject was hospitalized 
and was again diagnosed with pancreatitis. The subject was treated with 
intravenous fluids, pain medication, and antibiotics, and was discharged from 
hospital after 4 days. Elective laparoscopic cholecystectomy was conducted 6 
weeks later, at which time the subject had completed the blinded clinical study 
and had entered the open-label study. The event was considered resolved after a 
total duration of 93 days. Treatment with investigational product was continued 
throughout. The subject had no further episodes of abdominal pain and the 
investigator considered there was no reasonable possibility that the pancreatitis 
may have been caused by investigational product. In the investigator's opinion, 
the event was possibly associated with the subject's prior history of pancreatitis. 
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Patient K 
Suspect Drugs: Mepolizumab 
Serious Events: Pneumonia, Spinal compression fracture 
This 72-year-old female subject was enrolled in a blinded study for the treatment 
of hypereosinophilic syndrome. The subject developed a fever, arthralgia, 
weakness, dry cough, and myalgias 161 days after the start of treatment with 
intravenous investigational product. She was subsequently hospitalized for 
evaluation and treatment. Relevant test results revealed leukocytosis and 
increased neutrophils, and a chest x-ray showed a right upper lobe infiltrate. A 
sputum culture showed mixed normal flora. A nasopharyngeal wash for rapid 
RSV and influenza A were negative, as were cultures. She was diagnosed with 
pneumonia and began treatment with oxygen and levofloxacin (Levaquin). The 
event resolved after 35 days. The investigational product was continued. Current 
medical conditions included old age, long-term steroid use, spinal stenosis, and 
peripheral neuropathy with right foot drop. The investigator considered that there 
was no reasonable possibility that the pneumonia was related to investigational 
product, but was possibly associated with exposure to an infected source, as the 
subject worked in a hospital. 
Subsequently, 202 days after the start of investigational product and 7 
days after her most recent dose of investigational product, the subject walked to 
her kitchen without her leg brace, lost her balance, and fell on her back. She 
presented to the emergency department, where a spinal x-ray revealed a 
thoracic 12 compression fracture. The event was disabling. The event was 
resolving at the time of reporting—the subject was in a back brace with limited 
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mobility and was using a walker. Investigational product was continued. Magnetic 
resonance imaging 1 week later confirmed the T12 compression fracture but, 
given the degree of injury close to the spinal cord, surgery was not an option. 
The subject was treated with acetaminophen (Tylenol), dextropropoxyphene 
(Darvon), and Lortab plus a chest stabilizer brace and foot brace. The 
investigator considered there was no reasonable possibility that the T12 
compression fracture may have been caused by the investigational product, and 
that it was possibly associated with trauma. 
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Patient L 
Suspect Drugs: Placebo 
Serious Events: Nephrotic syndrome 
This 33-year-old male subject was enrolled in a blinded study for the treatment of 
hypereosinophilic syndrome. The subject received intravenous investigational 
product every 4 weeks for 175 days. The subject's past medical history included 
childhood asthma. Medical conditions at the time of the event included diabetes 
and hypertension. Concomitant medications included prednisone, Lorcet, 
glipizide, lisinopril, simvastatin, furosemide, and Hyzaar.  
Approximately 18 weeks after the start of investigational product, the 
subject presented to the emergency department with a 1-week history of pedal 
edema. He was treated with diuretics, but the edema progressed and 1 week 
later the subject was admitted to the hospital. Relevant test results included a 
decreased serum albumin and protein in the urine. The subject was diagnosed 
with nephrotic syndrome. A renal biopsy was performed, which showed findings 
diagnostic of a membranous glomerulopathy, stage I to II, with immune complex 
deposits and 10% to 15% chronicity, evocative of drug-related toxicity. Although 
a lupus-like condition could not be ruled out, the absence of immunofluoresence 
staining and reticular aggregates made this diagnosis less likely. There was no 
segmental glomerulosclerosis. Six of 22 glomeruli were globally sclerosed with 
periglomerular fibrosis. The findings suggested mild arterionephrosclerosis, but 
were not diagnostic of diabetic nephropathy. Other tests included negative 
hepatitis B and C panels and a normal serum electrophoresis. The subject also 
had a total protein value 5.9 g/L, albumin 2.5 g/L, blood urea nitrogen 26.0 
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mmol/L, creatinine 1.3 mg/dL, ALT 52.0 U/L, elevated white blood count 
14.0×109/L, and a hemoglobin value of 13.3 g/dL. At the time of the report, the 
event had improved and the subject had been discharged from the hospital (date 
not specified). The subject still had ongoing edema. Treatment with 
investigational product was continued. The investigator considered that there 
was no reasonable possibility that the nephrotic syndrome may have been 
caused by investigational product and cited that the event was possibly due to a 
medical condition and the prednisone taper from his study participation. The 
investigator reported that the subject was on prednisone 60 mg/day at study 
entry, which was then tapered to 20 mg/day, but was subsequently increased. 
The prednisone dose at event onset was 30 mg/day. Treatment with 
investigational product was discontinued after approximately 6 months, and the 
subject was withdrawn from the study. 
On follow-up, the investigator stated that no clear cause for the nephrotic 
syndrome could be identified. Also, the subject had no history of nephrotic 
syndrome or renal disease prior to study participation. At the time of reporting, 
the event was recovering but had not resolved. 
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Supplement Appendix 3. Figures 1 to 5 and Tables 1 to 9 Describing 
Additional Efficacy Data. 
 
Supplement Figure 1. Steroid Dose for Trial Completers Over Time. Top 
Panel Shows Patients Who Completed the Trial and Bottom Panel Shows 
Patients Who Withdrew From the Trial.  
 
a LOCF based on data from second infusion onwards. 
IV, intravenous; LOCF, last observation carried forward. 
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Supplement Figure 2. Mean Observed Eosinophil Counts for Trial 
Completers Over Time. Top Panel Shows Completers and Bottom Panel 
Shows Noncompleters.  
 
 
IV, intravenous. 
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Supplement Table 1a. Date of Withdrawal, Eosinophil Counts, and Steroid 
Dose for Placebo-Treated Patients Who Withdrew From the Study. 
 
Patient 
number/ 
day of 
withdrawal 
Baseline 
eosinophil 
count 
Last on-
treatment 
eosinophil 
count  
Baseline 
steroid 
dose 
Last on-
treatment 
steroid 
dose 
Number of 
day during 
the treatment 
period 
 
Cumulative 
Steroid dose 
during the 
treatment 
period  
Pt #15 
Day 57 
1000 1400 30 20 57 1830 
Pt #32 
Day 191 
730 1120 20 12.5 184 2020 
Pt #43 
Day 108 
790 1210 20 5 108 975 
Pt #61 
Day 106 
370 3830 50 12.5 84 3257.5 
Pt #101 
Day 146 
950 570 50 60 57 3030 
Pt #107 
Day 29 
1090 960 20 10 29 487.5 
Pt # 110 
Day 85 
180 220 45 20 85 1840 
Pt #126 
Day 134 
50 30 20 20 122 2512.5 
Pt #130 
Day 93 
NA 820 35 50 93 3460 
Pt # 136 
Day 224 
4690 2140 60 40 206 7330 
Pt #141 
Day 113 
190 460 25 50 113 4620 
Pt #142 
Day 113 
240 570 30 25 113 1960 
Pt # 151 
Day 57 
70 1440 40 20 57 1467.5 
Pt #152 
Day 113 
1860 3050 50 20 113 3075 
Pt #154 
Day 66 
NA 840 25 30 66 1127.5 
Pt #155 
Day 83 
950 1520 40 25 83 2112.5 
Pt #160 
Day 129 
30 360 NA 25 NA NA 
Pt #163 
Day 116 
60 560 30 17.5 61 1220 
Pt #164 
Day 185 
180 1170 20 10 175 2180 
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Pt #165 
Day 92 
2490 1960 37.5 21.9 88 2268.7 
Pt #170 
Day 89 
240 1450 50 40 88 3300 
Pt #171 
Day 139 
150 570 30 20 139 2877.5 
Pt #190 
Day 92 
3370 1280 50 50 92 3920 
Pt #194 
Day 143 
730 1410 25 17.5 142 3907.5 
Pt #200 
Day 56 
380 760 25 40 56 1720 
Pt #201 
Day 159 
190 730 30 20 120 2180 
Pt #227 
Day 169 
160 420 20 10 169 1864 
NA, not available. 
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Supplementary Table 1b: Date of Withdrawal, Eosinophil Counts and 
Steroid Dose for Mepolizumab-treated Patients Who Withdrew From the 
Study 
 
Patient 
number/ 
day of 
withdrawal 
Baseline 
eosinophil 
count 
Last on-
treatment 
eosinophil 
count  
Baseline 
steroid 
dose 
Last on-
treatment 
steroid 
dose 
Number of 
day during 
the 
treatment 
period  
Cumulative 
Steroid dose 
during the 
treatment 
period  
Pt #17 
Day 64 
250 90 20 15 58 820 
Pt #75 
Day 112 
100 200 30 0 112 1422.5 
Pt #85 
Day 57 
300 200 30 40 57 2070 
Pt #106 
Day 225 
80 80 20 0 144 1042.5 
Pt #125 
Day 188 
50 20 20 10 172 1935 
Pt #193 
Day 91 
550 40 30 25 91 1975 
Pt # 195 
Day 111 
200 2840 50 20 111 1855 
Reasons for withdrawal included lack of efficacy (based on eosinophil counts and HES clinical 
activity; n=5), adverse events (n=1), and withdrawal of consent (n=1) 
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Supplement Figure 3: Distribution of Corticosteroid Dose at Study End for 
a) Patients Who did not Achieve the Primary Endpoint; b) Patients Who did 
Achieve the Primary Endpoint; c) All Patients. Values Shown as Percent of 
Patients in Treatment Groups in Panels a) and b), and Individual Patient 
Values in c). 
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0
5
10
15
20
25
30
35
0 2.5 5 6.25 7.5 8 10 12.5 15 17.5 20 21.9 25 30 40 50 60
Prednisone dose (mg)
Placebo IV (n=24)
Mepolizumab IV (n=7)
Pr
op
or
tio
n 
of
 p
at
ie
nt
s 
(%
)
 
 
b) Prednisone dose at study end: responders
0
10
20
30
40
50
60
70
80
0 2.5 5 6.25 7.5 8 10 12.5 15 17.5 20 21.9 25 30 40 50 60
Prednisone dose (mg)
Placebo IV (n=18)
Mepolizumab IV (n=36)
Pr
op
or
tio
n 
of
 p
at
ie
nt
s 
(%
)
 
- 37 - 
 
 
0
5
10
15
20
25
30
35
40
45
50
55
60
Placebo IV
(n=42)
Pr
ed
ni
so
ne
 d
os
e 
(m
g)
•••
•
••
•••
•••••••
••
••
•••••••••
••••
•
••••
•••
•
Mepolizumab IV
(n=43)
••••••••••••••••••••••••
•
•••••••
•••
••
••
•
•
•
•
c) Prednisone dose at study end: all patients 
Horizontal bars represent the mean prednisone dose at the end of the study  
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Supplement Table 2. Summary of Patients Who Became Corticosteroid-
Free During Treatment Period. 
Baseline Prednisone 
Dose-Level Group Placebo IV Mepolizumab IV 
All subjects   
Number of 
subjects analyzed 
42 43 
Achieved 
corticosteroid-free 
status (%) 
10 (24) 34 (79) 
Odds ratio  12.80 
95% confidence 
interval for odds 
ratio 
 (4.39, 37.35) 
Chi-square value  26.24 
P-value  <0.001 
IV, intravenous. 
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Supplement Figure 4. Change in Mean Prednisone Dose From Baseline to 
Week 36. Missing data were calculated by last observation carried forward 
(LOCF). 
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Supplement Figure 5. Mean Prednisone Dose for Mepolizumab-Treated and 
Placebo-Treated Patients Comparing Responders and Nonresponders. Top 
Panel Shows Patients Who Achieved the Primary End Point and Bottom 
Panel Shows Patients Who Failed to Achieve the Primary End Point. 
 
 
a LOCF based on data from second infusion onwards. 
IV, intravenous; LOCF, last observation carried forward. 
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Supplement Table 3. Mean Laboratory Values of Interest for Inflammation 
and HES Subtype by Treatment and Response 
    Placebo Mepolizumab 
     Achieved 
Primary 
Endpoint 
Didn’t 
Achieve 
Primary 
Endpoint 
Achieved 
Primary 
Endpoint 
Didn’t 
Achieve 
Primary 
Endpoint 
Baseline  N 16 20 32 6 IgE antibody 
(KU/L) 
 Mean ± SD 1949±4497 1016±2454 511.4 ± 852 9991±23878 
  Median 211 120 154 103 
  Range 3,17185 4,9043 9,3165 8,58725 
 Week 
36  N 13 0 25 3 
  Mean ± SD 1429±4508  612±1040 24170±41025
  Median 68  152 788 
  Range 6,16415  12,4032 181,71540 
Baseline  N 16 20 33 6 Tryptase 
(UG/L) 
 Mean ± SD 6.1±4.16 9.2±12.6 5.6±3.1 6.2±5.3 
  Median 6.0 5.0 5.0 4.0 
  Range 1,14 2,57 2,14 2,16 
 Week 
36  N 13 0 23 3 
  Mean ± SD 6.5±4.4  5.9±3.3 2.3±0.6 
  Median 6.0  5.0 2.0 
  Range 2,15  1,13 2,3 
Baseline  N 16 21 33 6 Vitamin B12 
(PMOL/L) 
 Mean ± SD 379±333 394±154 375±342 256±85 
  Median 273 376 297 224 
  Range 137,1476 207,721 181,2196 170,412 
 Week 
36 
 N 13 0 25 2 
  Mean ± SD 330±146  435±284 266.0±81 
  Median 331  370 266 
  Range 130,604  179,1512 209,323 
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Supplementary Table 4a. Summary of prednisone dose at the end of the 
study: subjects who did not achieve a total daily prednisone dose of ≤10mg 
for a period of at least 8 consecutive weeks. 
 
Prednisone dose (mg) at 
the end of the study, n (%) 
Placebo IV (n=24) Mepolizumab IV (n=7) 
0 0/24 0/7 
2.5 0/24 0/7 
5 0/24 1/7 (14%) 
6.25 0/24 0/7 
7.5 0/24 0/7 
8 0/24 0/7 
10 1/24 (4%) 0/7 
12.5 1/24 (4%) 2/7 (29%) 
15 0/24 1/7 (14%) 
17.5  2/24 (8%) 0/7 
20 7/24 (29%) 1/7 (14%) 
21.875 1/24 (4%) 0/7 
25 4/24 (17%) 1/7 (14%) 
30 1/24 (4%) 0/7 
40 3/24 (13%) 1/7 (14%) 
50 3/24 (13%) 0/7 
60 1/24 (4%) 0/7 
 
- 43 - 
Supplementary Table 4b. Summary of prednisone dose at the end of the 
study: subjects who did achieve a total daily prednisone dose of ≤10mg for 
a period of at least 8 consecutive weeks. 
 
Prednisone dose (mg) at 
the end of the study, n (%) 
Placebo IV (n=18) Mepolizumab IV 
(n=36) 
0 3/18 (17%) 24/36 (67%) 
2.5 1/18 (6%) 1/36 (3%) 
5 2/18 (11%) 5/36 (14%) 
6.25 0/18 1/36 (3%) 
7.5 3/18 (17%) 2/36 (6%) 
8 0/18 1/36 (3%) 
10 6/18 (33%) 2/36 (6%) 
12.5 1/18 (6%) 0/36 
15 0/18 0/36 
17.5  0/18 0/36 
20 1/18 (6%) 0/36 
21.875 0/18 0/36 
25 0/18 0/36 
30 0/18 0/36 
40 1/18 (6%) 0/36 
50 0/18 0/36 
60 0/18 0/36 
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Supplementary Table 4c. Summary of prednisone dose at the end of the 
study: all patients randomized. 
 
Prednisone dose (mg) at 
the end of the study, n (%) 
Placebo IV (n=42) Mepolizumab IV 
(n=43) 
0 3/42 (7%) 24/43 (56%) 
2.5 1/42 (2%) 1/43 (2%) 
5 2/42 (5%) 6/43 (14%) 
6.25 0/42 1/43 (2%) 
7.5 3/42 (7%) 2/43 (5%) 
8 0/42 1/43 (2%) 
10 7/42 (17%) 2/43 (5%) 
12.5 2/42 (5%) 2/43 (5%) 
15 0/42 1/43 (2%) 
17.5  2/42 (5%) 0/43 
20 8/42 (9%) 1/43 (2%) 
21.875 1/42 (2%) 0/43 
25 4/42 (10%) 1/43 (2%) 
30 1/42 (2%) 0/43 
40 4/42 (10%) 1/43 (2%) 
50 3/42 (7%) 0/43 
60 1/42 (2%) 0/43 
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Supplement Table 5. Summary of Subjects Achieving the Primary End 
Point by End Organ Condition. 
 Current Condition Placebo IV Mepolizumab IV 
Yes 4/5 (80%) 5/5 (100%) 
Cardiac 
No 14/37 (38%) 31/38 (82%) 
Yes 1/3 (33%) 2/4 (50%) 
Eye 
No 17/39 (44%) 34/39 (87%) 
Yes 2/7 (29%) 8/8 (100%) 
Gastrointestinal 
No 16/35 (46%) 28/35 (80%) 
Yes 1/7 (14%) 5/6 (83%) 
Musculoskeletal 
No 17/35 (49%) 31/37 (84%) 
Yes 6/9 (67%) 8/9 (89%) 
Nervous system 
No 12/33 (36%) 28/34 (82%) 
Yes 7/16 (44%) 17/19 (89%) 
Respiratory 
No 11/26 (42%) 19/24 (79%) 
Yes 9/24 (38%) 11/16 (69%) 
Skin 
No 9/18 (50%) 25/27 (93%) 
IV, intravenous. 
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Supplement Table 6. Summary of Subjects Achieving the Primary End 
Point by Baseline Prednisone Dose. 
 Placebo IV Mepolizumab IV 
Total number of subjects 
achieving primary end point 
18/42 (43%) 36/43 (84%) 
Baseline prednisone dose (mg) 
12.5 0 1/1 (100%) 
17.5 0 1/1 (100%) 
20.0 13/15 (87%) 14/15 (93%) 
25.0 3/7 (43%) 4/5 (80%) 
30.0 0/6 6/8 (75%) 
35.0 0/1 1/1 (100%) 
37.5 0/1 0/1 
40.0 0/2 5/6 (83%) 
45.0 0/1 0 
50.0 1/6 (17%) 4/5 (80%) 
60.0 0/1 0 
Missing 1/2 (50%) 0 
IV, intravenous. 
- 47 - 
Results of the Rotterdam Symptom Checklist Subscale Assessments. 
At Weeks 24 and 36, greater proportions of subjects treated with mepolizumab 
reported having no HES symptoms based on the RSCL questions compared with 
those receiving placebo. However, there were no statistically significant 
differences in changes from baseline (improvement, no change, or deterioration) 
for any of the four RSCL subscales in either treatment group (Tables 7a and 7b 
below). This result is not unexpected since the placebo subjects that remained in 
the study were stable and responding well to prednisone alone. Further, the 
RSCL was developed for use in cancer patients with relatively early stage 
disease undergoing chemotherapy or follow-up. Its relevance and sensitivity in 
HES patients have not been previously tested and validated. 
 
Supplement Table 7a. Change from Baseline in Rotterdam Symptom 
Checklist Subscale Scores at the End of Treatment (ITT Population) 
 
 Placebo IV (n=42) Mepolizumab IV (n=43) 
RSCL Subscale, mean (SD)* 
Baseline 
(n=40) 
Change at 
Wk 36; 
LOCF† (n=35) 
Baseline 
(n=42) 
Change at 
Wk 36; 
LOCF† (n=39) 
Physical symptom distress 20.1 (15.4) 2.6 (8.7) 17.9 (13.2) −1.8 (9.6) 
Psychological symptom 
distress 
32.4 (21.7) −2.3 (17.3) 23.5 (18.7) −5.1 (17.7) 
Activities of daily living‡ 6.0 (12.1) 0.4 (13.7) 9.5 (17.7) 0.2 (13.1) 
Overall evaluation of life 32.9 (28.4) 8.6 (26.9) 23.0 (15.6) 6.4 (26.7) 
* Each of the RSCL subscales was transformed to give a range of scores from 0 to 100, with a 
higher score indicating a greater level of burden or impairment. 
†Last observation carried forward based on data from the 2nd infusion onwards 
‡n=41 at baseline for the mepolizumab group 
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Supplement Table 7b. Shift from Baseline in Rotterdam Symptom Checklist 
Subscale Scores at Each Visit (ITT Population) 
 
 Placebo IV (n=42) Mepolizumab IV (n=43) 
Subscale/Rating, n (%)  Wk 12 Wk 24 Wk 36 Wk 12 Wk 24 Wk 36 
Physical symptom distress level 
n 
Improved 
No change  
Deterioration 
 
30 
16 (53) 
0 
14 (47) 
 
15 
6 (40) 
0 
9 (60) 
 
12 
8 (67) 
0 
4 (33) 
 
36 
17 (47) 
0 
19 (53) 
 
30 
18 (60) 
1 (3) 
11 (37) 
 
28 
16 (57) 
4 (14) 
8 (29) 
Psychological symptom scores 
n 
Improved 
No change  
Deterioration 
 
30 
17 (57) 
3 (10) 
10 (33) 
 
15 
7 (47) 
4 (27) 
4 (27) 
 
12 
6 (50) 
2 (17) 
4 (33) 
 
36 
21 (58) 
4 (11) 
11 (31) 
 
30 
20 (67) 
4 (13) 
6 (20) 
 
28 
16 (57) 
2 (7) 
10 (36) 
Activities of daily living 
n 
Improved 
No change  
Deterioration 
 
29 
5 (17) 
16 (55) 
8 (28) 
 
15 
5 (33) 
8 (53) 
2 (13) 
 
12 
6 (50) 
5 (42) 
1 (8) 
 
35 
11 (31) 
19 (54) 
5 (14) 
 
29 
10 (34) 
16 (55) 
3 (10) 
 
27 
6 (22) 
16 (59) 
5 (19) 
Overall evaluation of life 
n 
Improved 
No change  
Deterioration 
 
30 
8 (27) 
11 (37) 
11 (37) 
 
15 
6 (40) 
5 (33) 
4 (27) 
 
12 
8 (67) 
1 (8) 
3 (25) 
 
36 
9 (25) 
14 (39) 
13 (36) 
 
30 
10 (33) 
10 (33) 
10 (33) 
 
28 
10 (36) 
7 (25) 
11 (39) 
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 Supplement Table 8a. Summary of subjects who became prednisone-free 
for ≥1 day, by baseline prednisone dose. 
 
 Placebo IV Mepolizumab IV 
Total subjects achieving 
endpoint, n (%) 
10/42 (24%) 34/43 (79%) 
Subjects achieving endpoint by baseline prednisone dose (mg), n (%) 
12.5 0 1/1 (100%) 
17.5 0 1/1 (100%) 
20 6/15 (40%) 14/15 (93%) 
25 3/7 (43%) 3/5 (60%) 
30 1/6 (17%) 5/8 (63%) 
35 0/1 1/1 (100%) 
37.5 0/1 0/1 
40 0/2 4/6 (67%) 
45 0/1 0 
50 0/6 5/5 (100%) 
60 0/1 0 
Missing 0/2 0 
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Supplement Table 8b. Summary of subjects who achieved a prednisone 
dose of ≤10 mg/day for ≥24 weeks, by baseline prednisone dose. 
 
 Placebo IV Mepolizumab IV 
Total subjects achieving 
endpoint, n (%) 
6/42 (14%) 24/43 (56%) 
Subjects achieving endpoint by baseline prednisone dose (mg), n (%) 
12.5 0 1/1 (100%) 
17.5 0 0/1 
20 6/15 (40%) 10/15 (67%) 
25 0/7 3/5 (60%) 
30 0/6 3/8 (38%) 
35 0/1 1/1 (100%) 
37.5 0/1 0/1 
40 0/2 4/6 (67%) 
45 0/1 0 
50 0/6 2/5 (40%) 
60 0/1 0 
Missing 0/2 0 
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Supplement Table 8c. Summary of subjects who became prednisone-free 
during the treatment period who remained prednisone-free until study 
completion, by baseline prednisone dose. 
 
 Placebo IV Mepolizumab IV 
Total subjects achieving 
endpoint, n (%) 
2/42 (5%) 20/43 (47%) 
Subjects achieving endpoint by baseline prednisone dose (mg), n (%) 
12.5 0 1/1 (100%) 
17.5 0 0/1 
20 2/15 (13%) 8/15 (53%) 
25 0/7 2/5 (40%) 
30 0/6 3/8 (38%) 
35 0/1 1/1 (100%) 
37.5 0/1 0/1 
40 0/2 4/6 (67%) 
45 0/1 0 
50 0/6 1/5 (20%) 
60 0/1 0 
Missing 0/2 0 
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Supplement Appendix 4. Listing of Serious Adverse Events Reported by Investigators from the Ongoing Open-Label 
Mepolizumab Extension Study, MHE100901, as of 3 September 2007 
As of 3 September 2007, the following serious adverse events have been reported by investigators participating in the ongoing 
extension study MHE100901; 61 of the 78 patients who initially enrolled continue participation in this study.  
Patient age, 
y & gender 
(M/F) 
Serious adverse 
event (SAE)* Intensity 
Date of 1st 
mepolizumab 
dose 
Date of last 
mepolizumab 
dose prior to 
onset of SAE 
No of doses of 
mepolizumab 
prior to SAE 
onset† 
Outcome Duration, days 
Relationship 
to study 
drug‡ 
Action taken 
58 (M) Ataxia Severe 4 Apr 2005 4 Jun 2007 28 Recovered/resolved 1 Not related No action 
 Confusion Severe 4 Apr 2005 4 Jun 2007 28 Recovered/resolved 1 Not related No action 
33 (M) Influenza Moderate 12 Jan 2006 9 Feb 2006 2 Recovered/resolved 5 Not related No action 
 Nephrotic syndrome Moderate 12 Jan 2006 2 Jun 2006 6 Not recovered/not resolved — Not related No action 
 Adrenal insufficiency Severe 12 Jan 2006 10 Aug 2006 8 Not recovered/not resolved — Not related No action 
 Eosinophilia Severe 12 Jan 2006 10 Aug 2006 8 Not recovered/not resolved — Not related No action 
 Hypertension  Severe 12 Jan 2006 10 Aug 2006 8 Not recovered/not resolved — Not related No action 
 Hypoglycemia Severe 12 Jan 2006 10 Aug 2006 8 Not recovered/not resolved — Not related No action 
 Hypokalemia Severe 12 Jan 2006 10 Aug 2006 8 Not recovered/not resolved — Not related No action 
 Nephrotic syndrome Severe 12 Jan 2006 10 Aug 2006 8 Not recovered/not resolved — Not related No action 
 Renal failure Severe 12 Jan 2006 10 Aug 2006 8 Not recovered/not resolved — Not related No action 
 Renal vein embolism Severe 12 Jan 2006 13 Oct 2006 9 Recovering/resolving — Not related Not applicable 
32 (F) Upper abdominal pain Severe 30 Sep 2005 29 Aug 2006 10 Recovered/resolved 6 Not related No action 
 Diarrhea Severe 30 Sep 2005 29 Aug 2006 10 Recovered/resolved 5 Not related No action 
 Pneumonia Moderate 30 Sep 2005 8 Jan 2007 11 Recovering/resolving — Not related No action 
61 (M) Acute cholecystitis Moderate 6 Dec 2005 6 Jun 2006 4 Recovered/resolved 2 Not related No action 
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23 (F) Thermal burn Moderate 26 May 2005 20 Oct 2006 21 Recovered/resolved 23 Not related No action 
37 (M) Optic neuritis Severe 14 Mar 2005 7 Sep 2006 13 Not recovered/not resolved — Related Dose interrupted 
 Spinal disorder Mild 14 Mar 2005 7 Sep 2006 13 Not recovered/not resolved — Related Dose interrupted 
 Myelitis transverse Severe 14 Mar 2005 7 Sep 2006 13 Not recovered/not resolved — Related Investigational product withdrawn 
 Catheter bacteremia Moderate 14 Mar 2005 7 Sep 2006 13 Recovering/resolving — Not related Not applicable 
53 (F) Pneumonia Moderate 16 Feb 2006 12 Feb 2007 13 Recovered/resolved 9 Not related No action 
65 (M) Dyspnea Moderate 22 Dec 2004 9 May 2005 6 Recovered/resolved 237 Not related No action 
 Status asthmaticus Severe 22 Dec 2004 9 May 2005 6 Recovered/resolved 220 Not related Dose interrupted 
57 (M) Fatigue Severe 12 Apr 2005 5 Dec 2006 21 Recovered/resolved 59 Not related Dose interrupted 
57 (M) Prostate cancer Severe 13 Sep 2005 3 Jan 2007 10 Recovered/resolved 74 Not related No action 
43 (F) Radiculitis brachial Severe 30 Sep 2004 13 Apr 2005 8 Recovered/resolved 61 Not related No action 
64 (F) Skin lesion (benign) Mild 3 Feb 2005 N/A N/A Recovered/resolved N/A Not related No action 
36 (F) Asthenia Moderate 7 Jul 2005 19 Jul 2007 6 Recovered/resolved with sequelae 2 Not related No action 
 Headache Moderate 7 Jul 2005 19 Jul 2007 6 Recovered/resolved with sequelae 2 Not related No action 
 Transient ischemic attack Moderate 7 Jul 2005 19 Jul 2007 6 
Recovered/resolved with 
sequelae 2 Not related No action 
58 (F) Hypertrophic rhinitis Moderate 21 Sep 2005 23 May 2006 2 Recovered/resolved 2 Not related No action 
62 (F) Upper respiratory tract infection Moderate 8 Nov 2005 28 Mar 2006 6 Recovered/resolved 18 Not related No action 
 Eosinophilia Moderate 8 Nov 2005 28 Mar 2006 6 Recovered/resolved 20 Not related No action 
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32 (F) Gastroenteritis Moderate 24 Mar 2005 28 Jul 2006 16 Recovered/resolved 2 Not related No action 
 Skin erosion Moderate 24 Mar 2005 28 Jul 2006 16 Not recovered/not resolved 164 Not related Dose interrupted 
 Cardiac failure Severe 24 Mar 2005 14 Dec 2006 18 Fatal 56 Not related No action 
 Acute renal failure Moderate 24 Mar 2005 14 Dec 2006 18 Recovered/resolved with sequelae 8 Not related No action 
 Calciphylaxis Moderate 24 Mar 2005 14 Dec 2006 18 Not recovered/not resolved 44 Not related No action 
 Autoimmune thrombocytopenia Severe 24 Mar 2005 14 Dec 2006 18 Recovered/resolved 5 Not related No action 
 Respiratory arrest Severe 24 Mar 2005 14 Dec 2006 18 Recovering/resolving 1 Not related No action 
 Sepsis Severe 24 Mar 2005 14 Dec 2006 18 Fatal 2 Not related Not applicable 
 Multi-organ failure Severe 24 Mar 2005 14 Dec 2006 18 Fatal 1 Not related Not applicable 
49 (M) Eosinophilic gastroenteritis Severe 22 Dec 2004 2 Oct 2006 14 Recovered/resolved 7 Not related Not applicable 
61 (M) Arterial occlusive disease Severe 23 Jun 2004 13 Mar 2006 15 
Recovered/resolved with 
sequelae 249 Not related Not applicable 
 Extremity necrosis Severe 23 Jun 2004 13 Mar 2006 15 Recovered/resolved 249 Not related Not applicable 
71 (M) Sclerosing cholangitis  Severe 4 May 2005 23 Aug 2006 12 Not recovered/not resolved 4 Not related No action 
 Hypotension Severe 4 May 2005 23 Aug 2006 12 Recovered/resolved 10 Not related No action 
 Clostridial gastroenteritis Severe 4 May 2005 23 Aug 2006 12 
Recovered/resolved with 
sequelae 8 Not related No action 
 Hypotension Severe 4 May 2005 23 Aug 2006 12 Not recovered/not resolved 14 Not related Investigational product withdrawn 
 Pneumonia aspiration Severe 4 May 2005 23 Aug 2006 12 Fatal 1 Not related Not applicable 
 Respiratory failure Severe 4 May 2005 23 Aug 2006 12 Fatal 1 Not related Not applicable 
28 (F) Depression Severe 3 Sep 2004 2 Sep 2005 14 Recovered/resolved 6 Not related No action 
 Depression Severe 3 Sep 2004 2 Sep 2005 14 Recovered/resolved 2 Not related No action 
 Asthma Severe 3 Sep 2004 30 Mar 2007 19 Recovered/resolved 4 Not related No action 
 Depression Severe 3 Sep 2004 10 Aug 2007 23 Recovered/resolved 1 Not related No action 
 Self-injurious ideation Severe 3 Sep 2004 10 Aug 2007 23 Recovered/resolved 1 Not related No action 
38 (M) Lymphomatoid papulosis Severe 4 Aug 2004 31 May 2005 11 Not recovered/not resolved — Not related No action 
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44 (M) Pancreatitis Severe 19 Oct 2004 7 Jun 2005 9 Recovered/resolved 93 Not related No action 
 Pancreatitis Severe 19 Oct 2004 5 Oct 2005 11 Recovered/resolved 4 Not related No action 
69 (M) Myocardial infarction Moderate 2 Aug 2004 4 Dec 2006 21 Recovered/resolved 1 Not related No action 
45 (M) Hypereosinophilic syndrome Severe 10 May 2004 8 Nov 2005 12 Recovered/resolved 8 Not related No action 
 Pyrexia Severe 10 May 2004 8 Nov 2005 12 Recovered/resolved 8 Not related No action 
34 (F) Dyspnea Moderate 28 Feb 2005 5 Dec 2006 13 Recovered/resolved 35 Not related No action 
66 (M) Influenza-like illness Mild 17 Nov 2004 6 Apr 2006 11 Recovered/resolved 2 Not related No action 
 Pyrexia Severe 17 Nov 2004 6 Apr 2006 11 Recovered/resolved 3 Not related No action 
 Osteoarthritis Severe 17 Nov 2004 6 Apr 2006 11 Recovered/resolved with sequelae 11 Not related No action 
53 (F) Bronchiectasis Moderate 10 Feb 2005 1 Sep 2006 12 Not recovered/not resolved — Not related No action 
46 (M) Angioimmunoblastic T-cell lymphoma Severe 12 Apr 2005 11 Oct 2006 19 Fatal 31 Related 
Investigational 
product withdrawn 
 Cardiopulmonary failure Severe 12 Apr 2005 11 Oct 2006 19 Fatal 8 Not related Not applicable 
38 (M) Pneumonia Severe 29 Mar 2005 10 Feb 2006 11 Recovered/resolved 9 Not related No action 
 
*A serious adverse event is defined as any event that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in a disability/incapacity, is a 
congenital anomaly/birth defect or is an important medical event 
†Total number of mepolizumab infusions in study MHE100185 and MHE100901 
‡The relationship between an SAE and the study drug was assessed by the investigator by responding 'yes' or 'no' to the following question, “Is there a reasonable possibility the SAE may 
have been caused by the study drug?” 
N/A, not available. Subject was not receiving mepolizumab when the event occurred (e.g., pre- or post-dosing) or the subject died and there was no prior decision to discontinue mepolizumab 
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Supplement Appendix 5. Baseline Demographics and Disease 
Characteristics in Subjects by Baseline Prednisone Dose Group (≤30 mg vs 
>30 mg). 
 
c ≤30 mg/day 
prednisone 
(n=60) 
>30 mg/day 
prednisone 
(n=25) 
Total  
(n=85) 
P-
value 
Age (yr) 51.3±14.7 40.2±14.1 48.1±15.3 <0.01 
Men, n (%) 30 (50) 13 (52) 43 (51) 0.87 
Race, n (%)*    ** 
White/Caucasian 53 (88) 19 (76) 72 (85)  
Black 4 (7) 4 (16) 8 (9)  
Asian† 2 (3) 1 (4) 3 (4)  
Arabic/North African 1 (2) 1 (4) 2 (2)  
Weight (kg) 81.6±20.6 77.3±19.7 80.3±20.3 0.39 
Body mass index (kg/m2) 27.7±6.2 26.8±6.1 27.4±6.1 0.57 
Previously treated for HES, n (%)‡ 56 (93) 25 (100) 81 (95) 0.19 
Most common discontinued previous treatments for HES, n (%)   
Any medication 32 (53) 19 (76) 51 (60) 0.05 
Imatinib mesylate 17 (28) 15 (60) 32 (38) <0.01 
Interferon-α 9 (15) 9 (36) 18 (21) 0.03 
Hydroxyurea 13 (22) 5 (20) 18 (21) 0.86 
Most common ongoing treatments for HES at screening, n (%)  
Any medication 47 (78) 23 (92) 70 (82) 0.13 
Systemic corticosteroids 47 (78) 23 (92) 70 (82) 0.13 
Interferon-α 2 (3) 1 (4) 3 (4) 0.88 
HES duration (yr) 4.6±6.5 7.3±10.3 5.4±7.8 0.14 
Age at HES onset (yr) 46.8±15.3 32.9±16.6 42.7±16.9 <0.01 
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 ≤30 mg/day 
prednisone 
(n=60) 
>30 mg/day 
prednisone 
(n=25) 
Total  
(n=85) 
P-
value 
Most prevalent HES-related current clinical conditions, n (%)§  
Any condition 49 (82) 21 (84) 70 (82) 0.80 
Skin/subcutaneous disorders 22 (37) 18 (72) 40 (47) <0.01 
Respiratory disorders 23 (38) 12 (48) 35 (41) 0.41 
Nervous system disorders 13 (22) 5 (20) 18 (21) 0.86 
Gastrointestinal disorders 11 (18) 4 (16)  15 (18) ** 
Musculoskeletal disorders 7 (12) 6 (24) 13 (15) ** 
Cardiac disorders 8 (13) 2 (8) 10 (12) ** 
Eye disorders 4 (7) 3 (12) 7 (8) ** 
Mean eosinophil count (×109/L) 0.295±0.279 0.812±1.140 0.447±0.694 0.03†† 
Median eosinophil count (GI/L) 0.200 0.260 0.200  
Serum Interleukin 5 (pg/mL)# All <7.8 8.7, 57, 72 N/A  
Mean serum tryptase level (µg/L) 7.3±7.9 
(n=56) 
5.9±5.6 
(n=22) 
6.9±7.3 
(n=78) 
0.16†† 
Median serum tryptase level (µg/L) 5.5 4.0  5.0  
Data are mean±SD unless otherwise specified.  
HES, hypereosinophilic syndrome; N/A, not available. 
*Assessed by investigator at screening. 
†Includes East, Southeast, and South Asian. 
‡Therapy for HES within 5 years prior to screening. 
§Patients may have had more than one HES-related current clinical condition. 
**As >50% of cells have expected counts less than 5, Chi-square test was not performed. 
††P-value based on Wilcoxon Rank Sum Test. 
#All but 3 patients were under the level of detection for the assay (7.8 ng/ml). The 3 individual 
patient levels are reported here. 
P-values are based on a 2-sided t-test with pooled variance (continuous data) or Chi-square test 
(categorical data), unless otherwise specified. 
 
